Quarterly Result14 Aug 2025, 04:17 pm
Indoco Remedies Ltd. Achieves 10.3% Growth in Domestic Formulation Business in FY 2024-2025
AI Summary
Indoco Remedies Ltd. has reported a 10.3% growth in its domestic formulation business in the financial year 2024-2025, with total income from operations at ₹ 1665 crores. The company invested in a Master Manufacturing Plan to bring in efficiencies and cater to the international market base. The R&D team successfully launched Lofexidine tablets and Lacosamide tablets and injections in the US market. Indoco is committed to ESG initiatives and various skill development training programmes for its employees. The company also continued its CSR activities, supporting individuals, communities, and NGOs in various fields.
Key Highlights
- Indoco Remedies Ltd. reports 10.3% growth in domestic formulation business in FY 2024-2025.
- Total income from operations stands at ₹ 1665 crores.
- Company invests in Master Manufacturing Plan to improve efficiencies and cater to international market base.
- R&D team successfully launches Lofexidine tablets and Lacosamide tablets and injections in the US market.
- Indoco continues its commitment to ESG initiatives and employee skill development training programmes.